Drug Metabolism Letters publishes letters, original research articles, mini-reviews, thematic issues based on mini-reviews and letters, commentaries, technical notes and drug clinical trial studies on major advances in all areas of drug metabolism and disposition.
In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; bioactivation; recent developments for the identification of drug metabolites, reactive intermediate and glutathione conjugates.
Zhiyang Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Tech, Blacksburg, Virginia, USA. Dr. Zhao’s biopharmaceutical/pharmaceutical work experience encompasses over 25 years of research in metabolic and pharmacokinetic properties of compounds for drug discovery and development at Pfizer, GlaxoSmithKline and Amgen. Currently, Dr. Zhao serve as Chief Scientific Officer (CSO) at Alliance Pharma, Inc. and appointed as an adjunct professor at the School of Pharmacy, the University of North Carolina at Chapel Hill. Dr. Zhao has published over 50 peer reviewed original research papers and patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology.